UK Statutory Scheme Rebate Rise Could Cause Product Shortages & Launch Delays
Executive Summary
The pharmaceutical industry is calling on the government to take steps to restore the UK as a location for life sciences investment and recognize the role of competition in the branded generics market, but it will need strong evidence to make the most convincing case.
You may also be interested in...
UK Industry Urges Government To Drop Statutory Pricing Scheme Rate Hike
The ABPI, which represents the R&D-based pharmaceutical industry in the UK, says the proposed increase in the statutory scheme rebate sends "the worst possible signal" to global investors and boardrooms.
More Execs Speak Out Over Risks Of UK Voluntary Pricing Scheme For Life Sciences
In 2022, a total of five companies chose to exit the UK’s voluntary scheme that manages branded medicines spending. The departure of two big firms – AbbVie and Lilly – is seen as a deliberate tactic to send a clear signal to government that the scheme is not working for industry and is jeopardizing investment and access to medicines in the UK.
UK Pharma Industry Facing Difficult Price Scheme Talks in 2023
Negotiations on the successor to the UK’s 2019 voluntary drug pricing scheme are due to start in April 2023. The industry body, the ABPI, is calling for a clean sheet approach, but others suggest that could make it almost impossible to reach agreement in less than a year and that reform may be a more realistic proposition.